Status:
NOT_YET_RECRUITING
A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
Lead Sponsor:
Ruijin Hospital
Conditions:
Peripheral T-cell Lymphoma (PTCL)
Eligibility:
All Genders
18+ years
Brief Summary
This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of th...
Eligibility Criteria
Inclusion
- Voluntarily sign and acknowledge understanding of the Informed Consent Form
- Clinically confirmed diagnosis of peripheral T-cell lymphoma
- Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months
- Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior/prescribed therapeutic regimens
Exclusion
- Poor patient adherence
- Investigator-deemed ineligibility for enrollment
Key Trial Info
Start Date :
April 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06963632
Start Date
April 30 2025
End Date
December 31 2027
Last Update
May 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.